Avid Bioservices Inc (CDMO)

[freethemice]

Thurly, I saw that the squamous patients in the first NSCLC trial had the lowest response rate.
However, that was based on 8 patients so I don't think you can make too much from that number.
Also, we don't know the survival numbers for those 8, it could be that their survival rate
did not reflect their response rate. In that same poster the info is given about the safety
and what prompted the suspension of enrollment for squamous patients. That event may
have been particular to that one patient because of the location of the tumor. Based on the MOA
for bavi I don't see why squamous patients would not benefit just as well as non-squamous patients.
Something for the future.
The ASCO 2010 poster is here:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=51223631